“Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s85. doi:10.25251/skin.4.supp.85.